FcγRIIB specific antibodies and methods of use thereof

• US 8,946,387 B2
• Filed: 08/05/2008
• Issued: 02/03/2015
• Est. Priority Date: 08/14/2002
• Status: Expired due to Fees

• Current Assignee: MacroGenics, Inc.
• Original Assignee: MacroGenics, Inc.
• Inventors: Koenig, Scott, Veri, Maria Concetta, Tuaillon, Nadine, Bonvini, Ezio
• Primary Examiner(s): DAHLE, CHUN WU
• Application Number:
  US12/186,065
• Publication Number:
  US 20090074771A1
• Time in Patent Office: 2,373 Days
• Field of Search: None
• US Class Current: 530/387.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 16/283 against Fc-receptors, e.g. CD16, CD32, CD64 CD23 C07K16/2851
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/71 Decreased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin'"'"'s lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

Claims

1. A bispecific antibody comprising:

(A) a first antigen binding polypeptide that selectively binds Fcγ

RIIB and comprises CDR1, CDR2 and CDR3 from an antibody heavy chain, and CDR1, CDR2 and CDR3 from an antibody light chain, wherein;

(1) said light chain CDR1 has a sequence of SEQ ID NO;

36, said light chain CDR2 has a sequence of SEQ ID NO;

37, and said light chain CDR3 has a sequence of SEQ ID NO;

38; and

(2) said heavy chain CDR1 has a sequence of SEQ ID NO;

27, said heavy chain CDR2 has a sequence of SEQ ID NO;

28, and said heavy chain CDR3 has a sequence of SEQ ID NO;

29,

and said first antigen binding polypeptide has the binding characteristics of an antibody produced from a hybridoma cell line having ATCC accession number PTA-4592; and

(B) a second antigen binding polypeptide, that specifically binds an activating receptor.

2. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide is a monoclonal antibody, a chimeric antibody, or humanized antibody, or fragment thereof.

3. The bispecific antibody of claim 1, wherein the second antigen binding polypeptide is a monoclonal antibody, a chimeric antibody, or humanized antibody, or fragment thereof.

4. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide has a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:

35.

5. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide has a light chain variable domain comprising the amino acid sequence of SEQ ID NO:

44.

6. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide comprises the variable regions of an antibody produced from a hybridoma cell line having ATCC accession number PTA-4592, or a fragment thereof.

7. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide is an antibody fragment selected from the group consisting of Fab, Fab′

, Fab2, Fab′

2, Fd, Fd′

, scFv, scFv2, and dAb.

8. The bispecific antibody of claim 1, wherein the second antigen binding polypeptide is an antibody fragment selected from the group consisting of Fab, Fab′

, Fab2, Fab′

2, Fd, Fd′

, scFv, scFv2, and dAb.

9. The bispecific antibody of claim 1, wherein the activating receptor is an IgE receptor.

10. The bispecific antibody of claim 9, wherein the IgE receptor is Fcε

RI.

11. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide is covalently bound to the second antigen binding polypeptide.

12. The bispecific antibody of claim 11, wherein the first and second antigen binding polypeptides are covalently bound via a linker comprising at least five amino acids.

13. The bispecific antibody of claim 1, wherein the bispecific antibody comprises a variant heavy chain hinge region incapable of inter-heavy chain disulfide linkage.

14. The bispecific antibody of claim 1, wherein the first antigen binding polypeptide binds human Fcγ

RIIB and demonstrates little or no binding to human Fcγ

RIIA.

15. A pharmaceutical composition comprising the bispecific antibody of claim 1, and a pharmaceutical carrier.

16. The composition of claim 15, wherein the first antigen binding polypeptide has a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:

35.

17. The composition of claim 15, wherein the first antigen binding polypeptide has a light chain variable domain comprising the amino acid sequence of SEQ ID NO:

44.

18. The composition of claim 15 further comprising an anti-IgE antibody or anti-IgE binding polypeptide.

19. The composition of claim 15 or 18, wherein the anti-IgE antibody is omalizumab.

20. A pharmaceutical composition comprising the bispecific antibody of claim 10, and a pharmaceutical carrier.

21. The composition of claim 20 further comprising an anti-IgE antibody or anti-IgE binding polypeptide.

22. A kit comprising the composition of claim 20 or 21, further comprising a label indicating that the bispecific antibody is for administration in combination with an anti-IgE antibody or anti-IgE binding polypeptide for the treatment of allergy, asthma or inflammation in a mammal.

23. The kit of claim 22, wherein the mammal is a human.

24. The kit of claim 22, wherein the administration of the bispecific antibody is separate from the anti-IgE antibody or anti-IgE binding polypeptide.

25. The kit of claim 24, wherein the anti-IgE antibody is omalizumab.